Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation)

Pearlie P. Chong; Dagny Teiber; Bonnie C. Prokesch; Reuben J. Arasaratnam; Matthias Peltz; Mark H. Drazner; Sonia Garg

doi:10.1111/tid.12965

Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation)

Pearlie P. Chong, Dagny Teiber, Bonnie C. Prokesch, Reuben J. Arasaratnam, Matthias Peltz, Mark H. Drazner, Sonia Garg

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Letermovir was approved by the Food and Drug Administration (FDA) in November 2017 for use in adult cytomegalovirus (CMV)-seropositive allogeneic stem cell transplant (SCT) recipients for primary prophylaxis of CMV infection and disease. We report off-label use of letermovir for secondary prophylaxis of genotype-confirmed ganciclovir-resistant cytomegalovirus (CMV) syndrome (UL 97 mutation [C603W]) in a heart transplant recipient initially treated with intravenous cidofovir followed by foscarnet, both discontinued due to unacceptable toxicities.

Original language	English (US)
Journal	Transplant Infectious Disease
DOIs	https://doi.org/10.1111/tid.12965
State	Accepted/In press - Jan 1 2018

Keywords

Cytomegalovirus
Ganciclovir resistance
Heart transplant
Letermovir
UL97 mutation

ASJC Scopus subject areas

Transplantation
Infectious Diseases

Access to Document

10.1111/tid.12965

Cite this

@article{35aa30dfa4624b48bd707697b047e1c3,

title = "Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation)",

abstract = "Letermovir was approved by the Food and Drug Administration (FDA) in November 2017 for use in adult cytomegalovirus (CMV)-seropositive allogeneic stem cell transplant (SCT) recipients for primary prophylaxis of CMV infection and disease. We report off-label use of letermovir for secondary prophylaxis of genotype-confirmed ganciclovir-resistant cytomegalovirus (CMV) syndrome (UL 97 mutation [C603W]) in a heart transplant recipient initially treated with intravenous cidofovir followed by foscarnet, both discontinued due to unacceptable toxicities.",

keywords = "Cytomegalovirus, Ganciclovir resistance, Heart transplant, Letermovir, UL97 mutation",

author = "Chong, {Pearlie P.} and Dagny Teiber and Prokesch, {Bonnie C.} and Arasaratnam, {Reuben J.} and Matthias Peltz and Drazner, {Mark H.} and Sonia Garg",

year = "2018",

month = jan,

day = "1",

doi = "10.1111/tid.12965",

language = "English (US)",

journal = "Transplant Infectious Disease",

issn = "1398-2273",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation)

AU - Chong, Pearlie P.

AU - Teiber, Dagny

AU - Prokesch, Bonnie C.

AU - Arasaratnam, Reuben J.

AU - Peltz, Matthias

AU - Drazner, Mark H.

AU - Garg, Sonia

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Letermovir was approved by the Food and Drug Administration (FDA) in November 2017 for use in adult cytomegalovirus (CMV)-seropositive allogeneic stem cell transplant (SCT) recipients for primary prophylaxis of CMV infection and disease. We report off-label use of letermovir for secondary prophylaxis of genotype-confirmed ganciclovir-resistant cytomegalovirus (CMV) syndrome (UL 97 mutation [C603W]) in a heart transplant recipient initially treated with intravenous cidofovir followed by foscarnet, both discontinued due to unacceptable toxicities.

AB - Letermovir was approved by the Food and Drug Administration (FDA) in November 2017 for use in adult cytomegalovirus (CMV)-seropositive allogeneic stem cell transplant (SCT) recipients for primary prophylaxis of CMV infection and disease. We report off-label use of letermovir for secondary prophylaxis of genotype-confirmed ganciclovir-resistant cytomegalovirus (CMV) syndrome (UL 97 mutation [C603W]) in a heart transplant recipient initially treated with intravenous cidofovir followed by foscarnet, both discontinued due to unacceptable toxicities.

KW - Cytomegalovirus

KW - Ganciclovir resistance

KW - Heart transplant

KW - Letermovir

KW - UL97 mutation

UR - http://www.scopus.com/inward/record.url?scp=85050557661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050557661&partnerID=8YFLogxK

U2 - 10.1111/tid.12965

DO - 10.1111/tid.12965

M3 - Article

C2 - 29989279

AN - SCOPUS:85050557661

SN - 1398-2273

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

ER -

Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this